Kornimate/medical-research-clean huggingface dataset:
interactive educational website for women with ovarian cancer & caregivers

Conditions: Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Recurrent Ovarian Cancer; Fallopian Tube Cancer

Summary: ovarian cancer accounts for more deaths than any other gynecologic malignancy. the majority of patients are diagnosed with stage iii-iv disease. nearly 80% of these patients will recur resulting in 5-year survival rates of 14-32%. although enrollment is increasing in hospice, hospice programs have been challenged to reach eligible patients. several factors limit the number of people who enroll in hospice and the length of their hospice stay. prognostication challenges and the increasing availability of cancer therapies for people with cancer set the stage for a mismatch between certification of a 6 month prognosis and contemporary medical care. additionally patients often are not aware of hospice and the services they can provide.

in this study, we will pilot-test a technology-based approach for women with stage iii/iv or recurrent ovarian cancer, their caregiver, and their providers to assist in and study the decision-making process that surrounds end-of-life decisions, specifically, opting for palliative care and/or entry into hospice care. we will randomize the women and their caregivers into either our intervention or control websites. all subjects will complete a battery of demographic, psychosocial, health status and outcomes, health information, and decision making measures at baseline and 60-day post-baseline. once the participant has completed the baseline survey, he/she will be automatically brought to their assigned website. both the patient and their caregiver will be assigned the same group (intervention or control). all participants will have open access to their respective study websites for a minimum of 60 days. during enrollment, participants will agree to access their respective websites at least 2-3 times per week. both patients and caregivers assigned to the control arm will view a website containing documents generally provided as part of the usual care. they will be requested to log in with the same frequency as the intervention group.

Eligibility criteria:
inclusion criteria: * women with stage iii, iv or recurrent ovarian, primary peritoneal or fallopian tube cancer or a nominated caregiver or such women * 18 years old or older * at least a 5th grade education * able to read and write in english * access to computer and internet * voluntary written informed consent before study entry, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care * no known major psychiatric or neurological diagnosis (schizophrenia or active chemical dependency) exclusion criteria: * borderline ovarian cancer

Keywords: stage iii ovarian cancer stage iv ovarian cancer recurrent ovarian cancer primary peritoneal cancer fallopian tube cancer
her2 treat study: retrospective study to estimate the prevalence of her2-low in unresectable and/or metastatic breast cancer patients who progress on anti-cancer therapy identified as her2-negative from patient medical records in the gulf cooperation council

Conditions: Breast Neoplasms; Breast Cancer; Breast Carcinoma; Genes; HER2

Summary: her2-low breast cancer (bc) has emerged as a new subtype of bc with distinct clinical, pathological, and prognostic features. little is known about the prevalence of the her2-low subtype in her2-negative patients, and previous reports showed variations in the criteria used to define the her2-low subtype. besides, data on the clinical features and prognosis of her2-low patients are limited, and it is still unclear whether her2-low bc has a prognostic value. identifying the prevalence and clinical features of her2-low bc can help establish a more accurate and reproducible definition of her2-low bc. in the gulf cooperation council (gcc) region, bc is the most common malignancy in women and still poses a significant burden on healthcare resource utilization, moreover, there is only one record for reimbursed her2 ihc status, categorized as her2-positive and her2-negative. it is important to understand the prevalence, clinical features, and outcomes of her2-low in bc patients from the gcc in this retrospective, non-interventional, multicenter study, the aim to describe the prevalence of her2-low bc among the current her2-negative bc population using rescored her2 ihc samples. the local treatment patterns and the outcomes will be analyzed using the information abstracted from the corresponding medical chart review. the study will cover the gcc region countries (united arab emirates \[uae\], saudi arabia, qatar, kuwait, and oman)


Eligibility criteria:
inclusion criteria: * women ≥ 18 years of age at date of diagnosis * patients must have a histological or cytological confirmed diagnosis of unresectable or/and mbc between 01st january 2018 and 31st december 2022. * patients with at least 12 months of follow-up data (from the index date) in the medical records at the participating site unless patient died. * patients must have been diagnosed as her2-negative (her2 ihc 0, 1+, 2+/ish-), regardless of hormone status. * patients who are diagnosed and/or progressed on at least one prior systemic anticancer therapy (e.g., et, chemotherapy, cdk4/6i, targeted therapies other than anti- her2, or immunotherapy) in the metastatic setting. * patients must have historical her2 fixed tissue ihc stained slides in acceptable quality to allow retesting of her2 expression only in case of the absence of accurate scoring of ihc/ish in pathology report. exclusion criteria: * have a history of other malignancies other than basal cell carcinoma of the skin and squamous cell carcinoma of the skin. * patients who are her2 positive (with historical her2 status of ihc 2+/ish+ or 3+, or her2 amplified.
usability study of cerebo® - a novel non-invasive intracranial bleed detector

Conditions: Traumatic Brain Injury; Intracranial Hemorrhages

Summary: traumatic brain injury (tbi) is the leading cause of death and disability across the globe. time from injury to treatment is the most critical factor that determines the patient's recovery. mild tbi with no apparent symptoms are often left undiagnosed, thus delaying the treatment and hence recovery. cerebo® is a non-invasive, rapid, near-infrared based, point-of-care device that can detect an intracranial bleed at an early stage.

this prospective study determines the usability of cerebo® to detect the intracranial hematoma. the operators will receive a training session before the study and will be evaluated at the end of the study through a survey questionnaire for ease of use, ease of learning and satisfaction. each operator will examine at least 10 subjects with cerebo®.

Eligibility criteria:
inclusion criteria: operators - medical health professionals \>18 years of age with a valid medical license to practice medicine belonging to one of the following categories and have given a written consent to participate in the study. 1. mbbs with specialisation 2. mbbs 3. nursing staff 4. others subjects - 1. subjects with suspected traumatic brain injury and gcs \> 13 2. of all ages and gender, have understood the study and gave a written informed consent. exclusion criteria: subjects - 1. subjects with active bleeding or scalp laceration 2. subjects with large extracranial lesions

Keywords: ease of use ease of learning satisfaction
seal, stopping eczema and allergy study

Conditions: Eczema, Infantile; Eczema; Atopic Dermatitis Eczema; Atopic Dermatitis

Summary: this is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (ad or eczema) by 12 weeks of age. the aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (epiceram) and proactive use of fluticasone propionate cream, against reactive ad therapy, to reduce the occurrence and severity of ad in early infancy and thereby prevent food allergy (fa).

this is a randomized, controlled, parallel design, open-label phase 2 clinical study to compare the efficacy of a proactive treatment arm versus the reactive arm, for the prevention of atopic dermatitis in children at high risk of food allergy. we will recruit 312 infants who have signs of dry skin or atopic dermatitis between 0-12 weeks of life. the aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (epiceram) and proactive use of fluticasone propionate cream, against reactive ad therapy, to reduce the occurrence and severity of ad in early infancy and thereby prevent food allergy (fa).

Eligibility criteria:
inclusion criteria: 1. participants who develop early onset visible dry skin or atopic dermatitis up to and equal to 12 weeks of age. 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. in good general health as evidenced by medical history 4. no known adverse reaction to any of the study medications, their components or excipients exclusion criteria: 1. infants \<3kg body weight 2. infants with a chronic disease requiring therapy (e.g. heart disease, diabetes, serious neurological defects, immunodeficiency) 3. known moderate to severe cutaneous skin disorder other than ad, including but not limited to cutaneous mastocytosis, bullous skin disease, pustular skin disease, neonatal hsv, aplasia, and albinism 4. parents or guardians unwilling to sign consent 5. current participant or participation since birth in any interventional study 6. investigator or designee considers that the participant or parent/guardian would be unsuitable for inclusion in the study (for ex/ long stay in nicu) 7. a course of antibiotics in infant within 7 days of enrollment 8. any known food allergies

Keywords: dermatitis dry skin food allergy moisturizer
connective tissue diseases and vitamin d deficiency

Conditions: Connective Tissue Diseases

Summary: connective tissue disease (ctd) covers all heterogeneous and broad immunological diseases. these immunological diseases are characterized by inflammation, tissue damage, and abnormal repair. disorders such as fibrotic tissue or loss of function are seen in the degeneration of the target organ. there is a complex relationship between genetic and environmental factors on the basis of these disorders. vitamin d deficiency has been frequently observed in autoimmune diseases such as systemic lupus erythematosus, diabetes mellitus, and rheumatoid arthritis. vitamin d deficiency is primarily seen with musculoskeletal complaints and is an early warning of osteomalacia. muscle weakness is most common in the trunk, shoulders and hips. it is characterized by difficulty in climbing stairs, getting up from sitting or lying position, feeling of heaviness in the legs, duck-like gait, difficulty getting up from a chair, fatigue easily, inability to lift objects with arms and hands. patients experience decreased exercise capacity as a result of pain and muscle weakness. in addition, vitamin d deficiency causes smooth muscle contraction and an increase in airway inflammation. as a result, it was observed that the disease course and symptoms were more severe in cvd patients with vitamin d deficiency. in a study conducted with rheumatoid arthritis patients, the quality of life, physical activity and depression levels of patients with vitamin d deficiency were compared with the control group. the evaluation parameters of rheumatoid arthritis patients were worse than the control group. vitamin d levels were compared with sleep, anxiety and depression levels in patients with systemic lupus erythematosus. a positive relationship was found between vitamin d deficiency and sleep disturbance level. it has been observed that the life expectancy of patients with connective tissue disease is significantly reduced compared to healthy ones. exercise capacity and oxygen consumption decreased in these patients.

outpatient connective tissue disease patients (systemic sclerosis and systemic lupus erythematosus) with stable medical conditions will be referred for physiotherapy and rehabilitation after being examined by the relevant physician. physiotherapy evaluation will be made by the physiotherapist. in addition; healthy individuals who accepted and gave consent to participate in the study without any chronic disease for the healthy control group will be included in the study.

Eligibility criteria:
inclusion criteria: * patients with stable general condition treated with standard medical treatment * patients between the ages of 18-65 exclusion criteria: * patients who cannot cooperate with the assessment * those who have orthopedic problems or neurological diseases that will affect the evaluation of functional capacity * patients with pneumonia or any acute infection at the time of assessment

Keywords: connective tissue disease muscle strength exercise capacity
nasal septum autologous chondrocytes transplantation for condylar resorption after orthognathic surgery

Conditions: Temporomandibular Joint Disorders

Summary: this clinical study has as main objective to evaluate if the nasal septum autologous chondrocytes transplantation for condylar resorption is safe and effective in the treatment of degenerative lesions of temporomandibular joint (tmj). it is a case series, in which 10 participants with diagnosis of condylar reabsorption of tmj will be selected, with orthognathic surgery indicated. orthognathic surgery is conventionally indicated for patients with condylar resorption to correct dentofacial deformity and, therefore, will not be performed only in function of this clinical study. the selected participants will be submitted to nasal cartilage biopsy, for isolation and preparation of the chondrocytes. the only experimental group to be evaluated will be the group treated with autologous chondrocytes diluted in hyaluronic acid. the experimental treatment will be performed 15 days after orthognathic surgery, and will be injected through arthrocentesis. clinical follow- up will be performed in the following periods: 7 and 15 days and 1, 3, 6 and 12 months after treatment. during the consultations, participants will also be evaluated for the intensity and severity of the pain experienced, as well as the disability related to it, through the same system used for the diagnostic classification (rdc / tmd). imaging of the tmj will be performed before, 6 and 12 months after the injection of the experimental treatment for bone and cartilaginous joint tissue analysis. autologous chondrocyte implantation is expected to promote the regeneration of tmj cartilage tissue safely and effectively.

the only experimental group to be evaluated will be the group treated with autologous chondrocytes diluted in hyaluronic acid, to be included in groups of 2, 4 and 4 participants. only two participants will initially be included. if these two treated participants do not present adverse effects in 3 months, we will start a second stage with 4 participants. again we will analyze the group over 3 months and if there are no problems we will include the 4 final participants, totaling the 10 participants.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of dentofacial deformities related to osteoarthritis of tmj; 2. must have surgical indication. exclusion criteria: 1. pregnant or breastfeeding; 2. infection or other comorbidities; 3. rheumatologic diseases; 4. chronic pain in another joint; 5. chronic use of corticosteroids and immunosuppressants.

Keywords: orthognathic surgery tmj osteoarthritis
does adding cryostimulation to conservative care help in managing chronic lateral epicondylitis? a pilote study

Conditions: Lateral Epicondylitis

Summary: in this study the investigators want to measure the impact or effects of adding cryostimulation to the conservative care of chronic lateral epicondylitis. the rapid fall in skin temperature above the injured tissues is presume to have a positive effect in the healing process. the combination of conservative care and cryostimulation could then be appreciated. the investigators chose to measure these effects with 3 elements: visual analog pain scale, validated elbow questionnaire and pain free grip strength. this pilot study consist in a two arm design, each arm including 15 patients.

lateral epicondylitis is one of the most prevalent upper limb conditions that can affect up to 1-3% of the active population. invalidity and health care costs incurred by this condition are posing a real challenge to our societies knowing that the natural history of the lateral epicondylitis can last from 1 to 2 years. many therapies have been tested and so far none has proven conclusive when used alone so far (blanchette and normand 2011). the use of cryostimulation is widespread in the sport scene without strong literature supporting its evidence. the aim of this study is to quantify the effects of cryostimulation when added to conservative care in the treatment of chronic lateral epicondylitis. thirty (30) patients will be divided randomly in two groups: * the control group (n=15) will receive conservative care including myofascial trigger points (involved forearm) and radial head mobilisations (bergmann \& peterson, 2010). * the experimental group (n=15) will receive the cryostimulation and the conservative treatment as mentioned above. a total of eight treatments will be given to each patient; the whole protocol lasting four to six weeks. the treatments will be delivered by experienced and trained clinicians in cryostimulation and myofascial treatment protocols. the effects of the two treatment protocols will be monitored by a validated elbow questionnaire (prtee, (rompe, overend et al. 2007)), a visual analog pain scale and the pain free grip strength at three moments: at inclusion, at the ninth visit and 3 months after the last treatment.

Eligibility criteria:
inclusion criteria: * must have pain at lateral elbow (lateral epicondylitis) for at least six months * pain must not come from trauma * painful palpation of the lateral epicondyle * at least one out of two positive test: cozen's, mill's exclusion criteria: * fibromyalgia * diabetes * patient taking more than three medications at the time of inclusion * cervical radiculopathy * painful shoulder * cold intolerance / allergies * smoking * cortisone infiltration at the painful lateral epicondyle in the month previous to the inclusion

Keywords: cryostimulation
biomarkers in obese patients with knee osteoarthritis; weight maintenance

Conditions: Osteoarthritis; Obesity

Summary: this is a substudy to a randomized trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (nct02905864). in the parent trial, patients will be subjected to an 8-week diet intervention phase including a low-calorie diet and dietetic counseling, after which they will be randomized to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle. this substudy aims to investigate the impact of, and subsequent change of biomarkers in obese patients with knee osteoarthritis following a randomization to liraglutide 3 mg or liraglutide 3 mg placebo treatment between weeks 0-52.


Eligibility criteria:
inclusion criteria: * same as parent trial (nct02905864) exclusion criteria: * same as parent trial (nct02905864)

Keywords: osteoarthritis obesity liraglutide 3 mg liraglutide biomarkers
response inhibition training for children with williams syndrome

Conditions: Williams Syndrome

Summary: the investigators will conduct a pilot study investigating the effectiveness of a computerized response inhibition training program at reducing the response inhibition difficulties often seen in children with williams syndrome ages 10-17. the investigators hypothesize that after completing the training program, children with williams syndrome will show improvement on computerized measures of response inhibition and on parent measures of impulsivity.

behavioral characteristics of individuals with williams syndrome include eagerness to approach and interact with others (including strangers), repeated questions especially about upcoming events, and difficulties with attention, impulsivity, and inhibition. there is very little systematic research about the kinds of interventions that are most useful for children with williams syndrome to support optimal psychosocial functioning, and of the effectiveness of such interventions. we will conduct a pilot study of a potential intervention to address the response inhibition difficulties associated with williams syndrome. the investigators will examine the utility of an online, web-based computerized cognitive retraining program aimed at addressing impulsivity and inhibition difficulties in 20 children, ages 10-17, with ws. the engaging training program has shown some utility in other populations, including children with tic disorders and trichotillomania. the investigators will examine the acceptability and feasibility of the treatment approach, as well as its impact on performance on experimental measures of impulsivity and on everyday psychosocial functioning as rated by parents; this study will consist of a small-scale pilot randomized clinical trial with wait list. through this novel work, we hope to develop and tune this approach for optimal outcomes and to demonstrate the promise of this intervention to address common challenges of people with williams syndrome in the area of inhibition.

Eligibility criteria:
inclusion criteria: * williams syndrome (diagnosed with genetic testing) * ages 10-17 * first language and main language spoken in the home is english * possess computer in the home that has internet access, and a second electronic device with access to skype (e.g., smartphone, ipad, additional computer, ipod touch) exclusion criteria: * first language and main language spoken in the home is not english (because study measures and instructions are all in english) * no computer in the home with internet access (because the study is being conducted via the internet) * comorbid severe illnesses or major surgery within the past 6 months * four or more previous sessions of inhibition training

Keywords: response inhibition, williams syndrome
clinical study between two clindamycin 1%/benzoyl peroxide 5% topical gels

Conditions: Acne Vulgaris

Summary: the purpose of this study is to compare the efficacy and safety profiles of perrigo israel pharmaceuticals, ltd. clindamycin 1%/benzoyl peroxide 5% topical gel and benzaclin® topical gel (clindamycin- benzoyl peroxide gel).


Eligibility criteria:
inclusion criteria: * healthy men or women, 12 to 65 years of age * willing to participate and sign provide written consent * moderate to severe acne exclusion criteria: * pregnant or lactating women * history of unresponsiveness or hypersensitivity to clindamycin, benzoyl peroxide or lincomycin * use of systemic, topical or facial products which may interfere with the study * participation in any clinical study in the 30 days prior to study entry * prolonged exposure to sunlight or excessive exposure to uv lights * chronic use of nsaids